Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31588788 | 0.85 | CYP2A6 (0.67) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL19386570 | 0.85 | CYP2A6 (0.51) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL3742332 | 0.83 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL29414360 | 0.83 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL2217042 | 0.83 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL3576292 | 0.83 | CYP2A6 (1.00) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL12304058 | 0.82 | CYP2A6 (0.63) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL3164828 | 0.81 | CYP2A6 (0.66) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL8547530 | 0.80 | CYP2A6 (0.75) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL2114297 | 0.79 | CA2 (0.55) | CYP2A6CA2MAPTTP53KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-06-05 | — | — | US | disclosed |
| WO-2025103442-A1 | SUBSTITUTED 2-(PYRROLIDIN-3-YL)ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| CN-113620950-A | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-109071542-B | Carboxamide derivatives useful as RSK inhibitors | 凤凰分子设计公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-3848373-A1 | N-(1-((HETEROCYCLYL)METHYL)-1H-PYRAZOL-4-YL)-6-OXO-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[L,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | Phoenix Molecular Designs (CA) | 2021-07-14 | — | — | EP | disclosed |
| EP-3848373-A1 | N-(1-((HETEROCYCLYL)METHYL)-1H-PYRAZOL-4-YL)-6-OXO-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[L,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | Phoenix Molecular Designs (CA) | 2021-07-14 | — | — | EP | disclosed |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2021-06-24 | — | — | US | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2020-09-01 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1362854-B1 | Benzo[b[thiophene derivatives and process for producing the same | TEIJIN PHARMA LTD (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-5792763-A | MIGRAINES; ANALGESICS; DISEASES LINKED TO DECREASED NEUROTRANMISSION OF SEROTONIN IN MAMMALS | ELI LILLY AND COMPANY (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1998015545-A1 | NEW SEROTONIN 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0835869-A2 | New serotonin 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | CYP2A6 688/4885CA2 1844/4885HDAC10 3129/4885 |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | CYP2A6 688/4885CA2 1844/4885HDAC10 3129/4885 |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | CYP2A6 1364/4885CA2 4199/4885HDAC10 2015/4885 |
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | PCSK9, LPL, LYPLA1 | CYP2A6 1329/4885CA2 2459/4885HDAC10 1504/4885 |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | RPS6KA5, RPS6KA2, RPS6KA1 | CYP2A6 2609/4885CA2 3492/4885HDAC10 112/4885 |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | CYP2A6 2270/4885CA2 3688/4885HDAC10 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.